Enveric Biosciences

03/31/2026

Enveric Biosciences has received U.S. Patent No. 12,577,232 (“the’232 patent”) from the USPTO pertaining to its EVM301 Series of molecules which includes lead candidate, EB-003. The patent provides added depth to Enveric’s EVM301 IP portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions. For details: https://bit.ly/4tjrD87

03/28/2026

Enveric today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025. See it here: https://bit.ly/4bCMVrz

03/19/2026

Our CEO, Joseph Tucker, Ph.D., comments on the registration of five trademarks that supports Enveric’s branding strategy for its future products. Learn more: https://bit.ly/4buehyK

03/18/2026

Enveric Biosciences announced that the Canadian Intellectual Property Office has registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences, as well as two “Plus Marks” which are designs used on Enveric product packaging, and its trademark, “Next Generation Mental Health.” For more details: https://bit.ly/4buehyK

03/10/2026

Our CEO, Joseph Tucker, sat down with Drug Discovery Online to discuss the shift in neuropsychiatric drug development toward neuroplastogens and Enveric’s lead candidate EB-003, which has been found to activate Gq- and β-arrestin signaling pathways linked to therapeutic-related brain biology. Read the interview here: https://bit.ly/46Ru89a

We caught up with Joseph Tucker, Ph.D., to discuss Enveric Bioscience’s focus on developing non-hallucinogenic neuroplastogenic compounds.

03/02/2026

A recent article in PharmaTech News details how the withdrawal of the Post Grant Review petition against Enveric’s ’276 patent reframes the neuroplastogen race and reinforces its positioning as a company with a strong IP foundation in next-generation, psychedelic-inspired drug development. Read it here:

In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court.

02/27/2026

Enveric’s CEO, Joseph Tucker, explains the potential benefits of EB-003's dual mechanism that selectively engages both the 5-HT2A and 5-HT1B receptors to promote neuroplasticity without triggering unwanted effects. Learn more in Drug Discovery News: https://bit.ly/3MQCUgH

02/27/2026

Medium details new insight into how Enveric's next-generation neuroplastogens, EB-003, may separate the therapeutic benefits of psychedelics from hallucinogenic effects, potentially making treatment for neuropsychiatric disorders more accessible. https://bit.ly/3Mowqpk

02/26/2026

Microdose details the withdrawal of a Post Grant Review petition filed against Enveric’s ‘276 patent, reinforcing the strength of the Company’s intellectual property estate for its pipeline of next-generation, psychedelic-inspired therapeutics. For more info, visit: https://bit.ly/3MM7ZlO

02/26/2026

Pharma Device News highlights the differentiated profile of Enveric’s neuroplastogen, EB-003, with preclinical data demonstrating a dual-pathway mechanism that activates therapeutic signaling downstream of the 5-HT2A receptor without inducing hallucinations, reinforcing the Company’s potential to deliver a more scalable and accessible treatment for neuropsychiatric disorders. Learn more: https://bit.ly/3OMcI7z

02/25/2026

Our CEO, Joseph Tucker, Ph.D., comments on the withdrawal of Gilgamesh's petition against Enveric’s ‘276 patent. For more details, visit: https://bit.ly/4scaxZv

02/25/2026

Enveric has announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) has been withdrawn. This action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result of this action, there are no remaining challenges currently pending against Enveric’s patent. https://bit.ly/4scaxZv